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Abstract
In the present study we sought to determine the effect of CoCl2, an inhibitor of PHD (prolyl hydroxylase domain
protein), on the development of AAA (abdominal aortic aneurysm). AAA was induced in C57BL/6 mice by periaortic
application of CaCl2 (AAA group). NaCl (0.9%)-treated mice were used as a sham control (SHAM group). Mice were
treated with 0.05% CoCl2 in the drinking water (AAA/CoCl2 group). At 1 and 6 weeks after the operation, aortic
tissue was excised for further examination. After 6 weeks of CaCl2 treatment, aortic diameter and macrophage
infiltration into the aortic adventitia were increased in the AAA group compared with the SHAM group. Treatment with
CoCl2 reduced the aneurysmal size and macrophage infiltration compared with the AAA group. Aortic expression of
inflammatory cytokines and MCP-1 (monocyte chemoattractant protein-1) and the activities of MMP-9 (matrix
metalloproteinase-9) and MMP-2 were enhanced in the AAA group and attenuated in the AAA/CoCl2 group.
Expression of cytokines and the activities of MMPs were already increased after 1 week of CaCl2 treatment, but
were suppressed by CoCl2 treatment in association with reduced NF-κB (nuclear factor κB) phosphorylation.
Treatment with CoCl2 in mice prevented the development of CaCl2-induced AAA in association with reduced
inflammation and ECM (extracellular matrix) disruption. The results of the present study suggest that PHD plays a
critical role in the development of AAA and that there is a therapeutic potential for PHD inhibitors in the prevention
of AAA development.
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INTRODUCTION
AAA (abdominal aortic aneurysm) is present in approximately
5–10 % of men older than 65 years of age [1,2]. Most of the
patients with AAA are asymptomatic and rupture may be
the first manifestation of the disease, which is lethal in most cases.
It is therefore important to diagnose AAAs in their early stages
and to prevent progression. However, effective treatments for the
Abbreviations: AAA, abdominal aortic aneurysm; CAT, catalase; DAB, diaminobenzidine; DMOG, dimethyloxaloylglycine; ECM, extracellular matrix; EPO, erythropoietin; EVG, elastica
Van Gieson; H/E, haematoxylin and eosin; HIF, hypoxia-inducible factor; HPRT, hypoxanthine phosphoribosyl transferase; IL, interleukin; LPS, lipopolysaccharide; MCP-1, monocyte
chemoattractant protein-1; MMP, matrix metalloproteinase; NF-κB, nuclear factor κB; PHD, prolyl hydroxylase domain protein; qRT-PCR, quantitative real-time reverse transcription– PCR;
ROS, reactive oxygen species; SOD1, superoxide dismutase 1; TNFα, tumour necrosis factor α; VEGF, vascular endothelial growth factor; VSMC, vascular smooth muscle cell.
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prevention of AAA enlargement have not been established, sug-
gesting that further clarification on the molecular mechanisms for
the development and progression of AAAs is needed to identify
effective therapeutic target molecules.
Previous studies have suggested that formation of AAAs is
closely associated with chronic inflammation of the aortic wall,
the local activation of proteinases and the degradation of mat-
rix proteins [3]. In contrast with the atherosclerotic plaque, of
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which inflammation is mainly observed in the intima, AAAs
are characterized by transmural inflammation. Degradation of
elastin in the media is also an important pathological feature of
AAAs [4]. Degradation of matrix proteins is due to MMPs (matrix
metalloproteinases) produced from infiltrated macrophages and
medial VSMCs (vascular smooth muscle cells). Transcription
factors, such as NF-κB (nuclear factor κB), are activated
and expression of pro-inflammatory cytokines, such as IL-6
(interleukin-6) and TNFα (tumour necrosis factor α), are in-
creased in AAAs [5,6].
PHD (prolyl hydroxylase domain protein) is responsible for
the degradation of HIF-1α (hypoxia-inducible factor α) protein,
a transcription factor activated in hypoxic conditions [7]. Hy-
droxylation of Pro402 and Pro564 of HIF-1α by PHD under nor-
moxic conditions results in the ubiquitination and subsequent
proteasomal degradation of HIF-1α. The activity of PHD is in-
hibited under hypoxic conditions and therefore HIF-1α is stabil-
ized. HIF-1α then heterodimerizes with constitutively expressed
HIF-1β and the resultant heterodimeric transcription factor HIF
activates transcription of many genes involved in the attenu-
ation of hypoxic damage, such as VEGF (vascular endothelial
growth factor) and EPO (erythropoietin). The activity of PHD
can be also inhibited by chemical inhibitors such as CoCl2 and
DMOG (dimethyloxaloylglycine) even under normoxic condi-
tions [8]. In addition to degradation of HIF-1α, recent stud-
ies have revealed HIF-independent function of PHD [9]. We
have reported previously that inhibition of PHD by chemical
inhibitors or siRNA-mediated down-regulation suppressed LPS
(lipopolysaccharide)-induced TNFα expression in a macrophage
cell line independently of HIF [10]. These results prompted us
to investigate whether inhibition of PHD attenuates the devel-
opment of AAAs, in which inflammation plays an important
role.
MATERIALS AND METHODS
Murine AAA model
All procedures were approved by the Animal Care and Use Com-
mittee of Kyushu University and were conducted in accordance
with the institutional guidelines. AAA formation was induced
in 6–7-week-old C57BL/6 mice by periaortic application of 0.5
mol/l CaCl2 (Wako) as described previously [11], under anaes-
thesia by intraperitoneal injection of ketamine (100 mg/kg of
body mass) and xylazine (10 mg/kg of body mass). The mice
were purchased from Clea Japan and fed on a normal chow. Ap-
plication of the appropriate level of anaesthesia was confirmed by
the absence of a withdrawal response to a hard pinch of the foot.
NaCl (0.9 %) was substituted for CaCl2 in the sham-operated
mice (SHAM group; n= 44). Mice were treated with 0.05 %
CoCl2 (Sigma–Aldrich) dissolved in water (AAA/CoCl2 group;
n= 44) or drinking water alone (AAA group; n= 44) for 1 week
before the operations were performed. The estimated daily intake
of CoCl2 was 70 mg/kg of body mass.
At 1 and 6 weeks after the operations were performed,
the blood pressures and heart rates of the mice were meas-
ured using the tail-cuff method while in a conscious
state (BP-98A-L; Softron). The mice were then anaes-
thetized by intraperitoneal injection of ketamine (100 mg/
kg of body mass) and xylazine (10 mg/kg of body mass) and
perfusion-fixed with 10 % formaldehyde in PBS at physiolo-
gical perfusion pressure. The abdominal aorta was carefully
excised so as not to disturb the adventitia and photographed
to determine its external diameter. Aortic diameter was meas-
ured using computer-assisted image analysis software ImageJ
(http://rsb.info.nih.gov/ij/). The aortic tissue was then subjected
to histological analyses.
Histological analysis
Paraffin-embedded cross-sections of abdominal aorta (6-μm
thick) were subjected to H/E (haematoxylin and eosin) and
EVG (elastica Van Gieson) staining. For Mac-2 [also known
as Lgals3 (galectin-3)] immunohistochemical staining, paraffin-
embedded tissue sections were deparaffinized and rehydrated
and then autoclaved in 10 mmol/l citrate buffer for anti-
gen retrieval. Following quenching with endogenous peroxi-
dase, sections were incubated with an anti-(mouse Mac-2) an-
tibody (Cedarlane) at 4 ◦C overnight. After incubation with
Simple Stain MAX-PO (Rat) (Nichirei Bioscience), sections
were incubated in DAB (diaminobenzidine) solution and coun-
terstained with haematoxylin. The number of Mac-2-positive
cells was quantified by counting the total number of DAB-
positively stained cells in 20 grid fields with a total area
of 0.1 mm2.
qRT-PCR (quantitative real-time reverse
transcription–PCR)
The infrarenal portion of the aorta was removed, minced
into small pieces, homogenized in ISOGEN solution (Nip-
pon Gene) on ice and total RNA was extracted accord-
ing to the manufacturer’s protocol. A 1 μg sample of total
RNA of the aorta was reverse-transcribed with the Rever-
Tra Ace qPCR RT kit (Toyobo). Real-time qPCR analysis
was performed using the Power SYBR Green PCR Master
mix (Life Technologies) and the Applied Biosystems 7500
Real-Time PCR system according to the manufacturer’s pro-
tocol. Expression of IL-1β, IL-6, MCP-1 (monocyte chemoat-
tractant protein-1), TNFα, MMP-2 and MMP-9 are shown
as the relative mRNA level of HPRT (hypoxanthine phos-
phoribosyl transferase) using the comparative CT (CT)
method. The following primers were used: IL-1β, 5′-TCC-
AGGATGAGGACATGAGCAC-3′ (forward) and 5′-GAAC-
GTCACACACCAGCAGGTTA-3′ (reverse); IL-6, 5′-CCACT-
TCACAAGTCGGAGGCTTA-3′ (forward) and 5′-GCAAGT-
GCATCATCGTTGTTCATAC-3′; MCP-1, 5′-GCATCCACGT-
GTTGGCTCA-3′ (forward) and 5′-CTCCAGCCTACTCAT-
TGGGATCA-3′ (reverse); TNFα, 5′-AAGCCTGTAGCCCA-
CGTCGTA-3′ (forward) and 5′- GGCACCACTAGTTGGTT-
GTCTTTG-3′ (reverse); HPRT, 5′-TTGTTGTTGGATATGC-
CCTTGACTA-3′ (forward) and 5′- AGGCAGATGGCCA-
CAGGACTA-3′ MMP-2, 5′-GATAACCTGGATGCCGTCGTG-
3′ (forward) and 5′-CTTCACGCTCTTGAGACTTTGGTTC-3′
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Table 1 Body mass and haemodynamics
Results are means +− S.D. b.p.m., beats/min.
(a) After 1 week
Parameter SHAM (n=5) AAA (n=5) AAA/CoCl2 (n=5)
Body mass (g) 19.1 +− 0.44 19.2 +− 0.50 18.7 +− 0.64
Systolic blood pressure (mmHg) 103 +− 7 105 +− 6 102 +− 6
Heart rate (b.p.m.) 560 +− 10 570 +− 9 561 +− 11
(b) After 6 weeks
Parameter SHAM (n=8) AAA (n=10) AAA/CoCl2 (n=8)
Body mass (g) 24.5 +− 2.3 25.1 +− 1.3 24.6 +− 1.6
Systolic blood pressure (mmHg) 105 +− 8 107 +− 9 105 +− 8
Heart rate (b.p.m.) 562 +− 32 578 +− 26 588 +− 31
(reverse); MMP-9, 5′-CATTCGCGTGGATAAGGAGT-3′ (for-
ward) and 5′-ACCTGGTTCACCTCATGGTC-3′ (reverse);
SOD1 (superoxide dismutase 1), 5′-AGCATTCCATCATTGG-
CCGTA-3′ (forward) and 5′-TACTGCGCAATCCCAATCA-
CTC-3′ (reverse); CAT (catalase), 5′-TCTACACAAAGGT-
GTTGAACGAGGA-3′ (forward) and 5′-AGTCAGGGTGG-
ACGTCAGTGAA-3′ (reverse); and VEGF, 5′-GCACAT-
AGGAGAGATGAGCTTCC-3′ (forward) and 5′-CTCCGC-
TCTGAACAAGGCT-3′ (reverse).
Gelatin zymography
To estimate the activities of MMP-2 and MMP-9, gelatin zymo-
graphy was performed using extracts from AAA tissue. Frozen
descending aorta was homogenized in lysis buffer composed
of RIPA buffer, 1 % aprotinin, 10 μmol/l pepstatin A, 1 mmol/l
PMSF and 2.5 μg/ml leupeptin. After centrifugation at 12 000 g
for 20 min at 4 ◦C the supernatant was collected. An equal amount
of protein (15 μg) was subjected to SDS/PAGE (10 % gel) co-
polymerized with 0.1 % gelatin as a substrate. Gels were washed
with 2.5 % Triton X-100 and incubated at 37 ◦C for 48 h with reac-
tion buffer (50 mM Tris/HCl, pH 6.8, containing 10 mM CaCl2)
and then stained with staining buffer (0.8 % Brilliant Blue R) so
that protein bands with gelatinolytic activity were easily identi-
fied as clear lytic bands. Band intensities were quantified using
ImageJ software. The total of MMP-2 and pro-MMP-2 or MMP-
9 was measured as the total MMP-2 or MMP-9 activity. Human
MMP marker (Primary Cell) was used to determine the molecular
mass.
Western blot analysis
For Western blotting, preparation of aortic tissue lysate was
performed as described above. Equal amounts (10 μg) of pro-
tein samples were subjected to SDS/PAGE and transferred on
to PVDF membranes (Immobilon-P; Millipore). After blocking
with 5 % dried non-fat skimmed milk powder, the membrane
was incubated with the primary antibodies against phospho-p65
and p65 (Cell Signaling Technology), followed by exposure to
the secondary antibody. Actin (Santa Cruz Biotechnology) im-
munoblotting was used as a protein loading control. Blots were
detected using an ECL Prime Western Blotting Detection reagent
(GE Healthcare). The signals were quantified by ImageJ software.
Statistical analysis
The experimental data were analysed by one-way ANOVA and
Tukey’s HSD (honestly significant difference) test. Steel–Dwass
tests were used if the data were not normally distributed. Res-
ults are means +− S.E.M. or S.D. and P< 0.05 was considered
statistically significant.
RESULTS
PHD inhibition by CoCl2 prevents the development
of AAA
The body mass, blood pressure and heart rate were comparable
among the three groups after 1 and 6 weeks (Table 1). No ob-
vious toxicity of CoCl2 treatment was observed. No significant
changes in aortic diameter were observed after 1 week of CaCl2
treatment (results not shown). The maximal external diameter
of the abdominal aorta at 6 weeks was larger in the AAA group
than in the SHAM group (P< 0.01). Dilatation of the aorta was
attenuated in the AAA/CoCl2 compared with the AAA group
(P< 0.01) (Figures 1A and 1B).
PHD inhibition by CoCl2 attenuated inflammation
and preserved ECM (extracellular matrix) structure
H/E staining showed enlargement of the luminal area, modest
thinning of the media and marked thickening of the adventi-
tia in the AAA group after 6 weeks (Figures 1C–1H). However,
these changes were attenuated by CoCl2 treatment. EVG staining
showed the wavy structure of the elastic lamellae in the SHAM
group, which was lost in the AAA group (Figures 1I–1N). Treat-
ment with CoCl2 preserved the elastin structure of the aorta.
Immunohistochemical staining for macrophages with an anti-
Mac-2 antibody showed a marked infiltration of macrophages
into the adventitia of the aorta in the AAA group (Figures 1O–
1R). CoCl2 treatment decreased the number of infiltrated Mac-2-
positive macrophages (Figures 1O and 1P).
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Figure 1 Inhibition of PHD by CoCl2 attenuated CaCl2-induced AAA in mice
(A) Representative macroscopic appearances of the aorta in sham-operated control mice (SHAM), AAA mice (AAA) and
CoCl2-treated AAA mice (AAA/CoCl2) after 6 weeks are shown. (B) The maximum external diameter of the abdominal aorta
after 6 weeks of CaCl2 treatment is larger in the AAA group than in the SHAM group. The diameter is smaller in the
AAA/CoCl2 group than in the AAA group. Results are means +− S.E.M. (n= 10 for each group). ∗P< 0.05 compared with
the SHAM group and †P< 0.05 compared with the AAA group. (C–N) Representative microphotographs of the H/E (C and
F, SHAM; D and G, AAA; and E and H, AAA/CoCl2) and EVG (I and L, SHAM; J and M, AAA; and K and N, AAA/CoCl2)
staining of the aortic wall. Scale bars, 100 μm in (C–E and I–K) and 50 μm in (F–H and L–N). (O–Q) Immunohistochemical
staining for Mac-2 in the mouse aortic wall. Scale bars, 100 μm. (R) Mac-2-positive cells were counted in each slice and
are indicated as the number of cells per mm2. Results are means +− S.E.M. (SHAM, n= 7; AAA, n= 10; and AAA/CoCl2,
n= 8). ∗P< 0.05 compared with the SHAM group and †P< 0.05 compared with the AAA group.
PHD inhibition by CoCl2 reduced the expression of
inflammatory cytokines
We examined the expression of inflammatory cytokines in the
aortic walls after 1 week of CaCl2 application (Figure 2A), when
enlargement of the aorta is minimal [12]. Expression of IL-1β,
IL-6 and MCP-1 was up-regulated in the AAA group com-
pared with the SHAM group. Expression of IL-1β, IL-6 and
MCP-1 was significantly suppressed in the AAA/CoCl2 group.
However, we did not observe any effect of CoCl2 on TNFα
expression.
qRT-PCR analysis of the mRNA at the aneurysmal sites after
6 weeks of CaCl2 treatment revealed up-regulation of IL-1β, IL-
6, MCP-1 and TNFα in the AAA group compared with the
SHAM group (Figure 2B). Although the mRNA level of IL-
1β, IL-6, MCP-1 and TNFα showed a trend towards a reduction
in the AAA/CoCl2 group, the difference was not statistically
significant.
The mRNA expression ofVEGF, a target gene ofHIF, was in-
creased after both 1 and 6 weeks, suggesting that CoCl2 treatment
suppressed PHD activity and thereby activated HIF.
PHD inhibition by CoCl2 restored the expression of
antioxidant genes
In the AAA group, expression of SOD1 and CAT were down-
regulated compared with the SHAM group after 1 week of CaCl2
treatment. At the same time point the expression of SOD1 and
CAT were reversed in the AAA/CoCl2 group (Figure 2A). Al-
though the mRNA levels of SOD1 and CAT after 6 weeks of
CaCl2 treatment showed a trend towards an increase in the
AAA/CoCl2 group compared with the AAA group, the differ-
ence was not statistically significant (Figure 2B). The expression
of the Nox2, Nox4 and p47 NADPH oxidase subunits was not
changed significantly among the three groups after both 1 and
6 weeks (results not shown).
PHD inhibition by CoCl2 suppressed the activity of
MMPs
We examined the effect of CoCl2 treatment on MMP activity by
gelatin zymography. Gelatin zymography showed that the abund-
ance of the active forms of MMP-9 and MMP-2 in the aortic
walls was up-regulated strongly after 1 week (Figures 3A–3C)
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Figure 2 Inhibition of PHD by CoCl2 attenuated the expression of pro-inflammatory cytokines in CaCl2-treated aortas
(A) Expression levels of IL-1β, IL-6, MCP-1, TNFα, SOD1, CAT, MMP-2, MMP-9 and VEGF in the aorta of CaCl2- or sa-
line-treated sites after 1 week. Expression of each gene is shown as the relative mRNA level to that of HPRT. Expression
levels in the saline-treated aortas (SHAM) were set to 1. Results are means +− S.E.M. (n= 5 for each group). ∗P<0.05
compared with the SHAM group and †P<0.05 compared with the AAA group. (B) Expression levels of IL-1β, IL-6, MCP-1,
TNFα, SOD1, CAT, MMP-2, MMP-9 and VEGF at aneurysmal sites after 6 weeks are expressed as the ratio of those at
sites treated with saline (SHAM). Expression of each gene was presented as the relative mRNA level to that of HPRT.
Expression levels in the saline-treated aortas (SHAM) were set to 1. Results are means +− S.E.M. (n= 10 for each group).∗P<0.05 compared with the SHAM group and †P<0.05 compared with the AAA group.
and increased modestly after 6 weeks (Figures 3D–3F) of CaCl2
treatment in the AAA group compared with the SHAM group.
Their abundances were decreased by CoCl2 treatment.
The mRNA levels of MMP-2 and MMP-9 were increased
greatly after 1 week of CaCl2 treatment (Figure 2A), which was
suppressed significantly by CoCl2 treatment.MMP-9mRNA was
still significantly increased after 6 weeks, but the increase in
MMP-2 expression was not significant (Figure 2B). The effect
of treatment with CoCl2 on MMP-2 and MMP-9 expression was
not observed at this point.
PHD inhibition by CoCl2 suppressed p65
phosphorylation of NF-κB
NF-κB plays an important role in the up-regulation of inflammat-
ory cytokines and MMPs. Protein expression of the p65 subunit
of NF-κB was increased slightly in the AAA group; however, the
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Figure 3 Inhibition of PHD by CoCl2 suppressed MMP activity in
the aortic wall after 1 and 6 weeks of CaCl2 treatment
Representative gelatin zymography images after 1 week (A–C) and
6 weeks (D–F) of saline (SHAM) or CaCl2 treatment (AAA). Represent-
ative photographs of the gels are shown. The left-hand lane is the
MMP marker derived from human fibrosarcoma cells and the bands
showed pro-MMP-9 (92 kDa), pro-MMP-2 (66 kDa) and MMP-2 (62 kDa)
according to the manufacturer’s instructions. Densitometric analysis
of the gels was performed for MMP-9 (B and E) and MMP-2 (C and
F). The abundance of MMPs in the SHAM group was set to 1. Res-
ults are means +− S.E.M. (1 week, n= 4 and 6 weeks, n= 8). ∗P< 0.05
compared with the SHAM group and †P< 0.05 compared with the AAA
group.
difference was not statistically significant. The phosphorylation
level of p65 was significantly greater in the AAA group than the
SHAM group. Treatment with CoCl2 significantly attenuated the
phosphorylation of p65 (Figure 4).
DISCUSSION
In the present study, we have shown that treatment with CoCl2
attenuated the CaCl2-induced dilatation of the abdominal aorta
in association with a reduction in inflammatory cytokine ex-
pression, MMP activity and NF-κB phosphorylation. The causal
relationship between the reduction in cytokines and MMPs and
Figure 4 Inhibition of PHD by CoCl2 suppressed p65 phosphoryla-
tion in the aortic wall after 1 week
(A–C) Representative immunoblotting analysis of phospho-p65 and p65
of NF-κB in the mouse aortic wall lysate. Results are means +− S.E.M.
(n= 6 for each group). Because the expression of p65 was mildly in-
creased in the AAA group, the p65 and phospho-p65 levels were normal-
ized to the β -actin expression. Histograms indicate the relative ratio of
phospho-p65 to β -actin (B) and p65 to β -actin (C). ∗P< 0.05 compared
with the SHAM group and †P< 0.05 compared with the AAA group.
the suppression of AAA formation is not clear from the present
study. However, CoCl2 treatment suppressed cytokine expres-
sion and MMP activity after 1 week of CaCl2 treatment, when
dilatation of the aorta is minimal in this model [12]. Therefore
the suppression of cytokines and MMPs by CoCl2 treatment
may be involved in the attenuation of AAA formation in our
model.
The effect of cobalt on inflammation is controversial. Kalpana
et al. [13] reported that hypoxia-induced NF-κB activation in
the rat brain was inhibited by pre-treatment with CoCl2. Co-
balt suppressed the hypoxia-induced NF-κB activation and the
production of ROS (reactive oxygen species), resulting in the
suppression of the production of MCP-1 and IFNγ (interferon
γ ). These data are consistent with the present study and our pre-
vious study that DMOG, another PHD inhibitor, or knock down
of PHD suppressed LPS-induced expression of TNFα, IL-6 and
IL-1β in association with the suppression of NF-κB-dependent
gene transcription in macrophages [10]. Another study reported
renal protection by CoCl2 [14]. Treatment of hypertensive rats
with Type 2 diabetes and nephropathy with CoCl2 attenuated
proteinuria. The reduction of proteinuria was associated with at-
tenuation of kidney injury and suppression of Nox2, a subunit
of NADPH oxidase, and TGF-β (transforming growth factor-β)
expression. Treatment with cobalt also attenuated cyclosporine
A-induced tubulointerstitial injury in association with a reduc-
tion in macrophage infiltration into the renal tubulointerstitium
[15]. Cobalt suppressed cyclosporine A-induced NF-κB phos-
phorylation, a marker of its activation, in human renal tubular
epithelium cells. The results of these studies and the present
study suggest that CoCl2 suppresses inflammation. Activation of
HIF by cobalt-mediated PHD inhibition is proposed to be in-
volved in the anti-inflammatory effect. Although we confirmed
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PHD inhibition/HIF activation in the AAA/CoCl2 group by up-
regulation of VEGF mRNA in the aorta, the role of HIF in the
anti-inflammatory effects of CoCl2 remains to be determined.
In contrast, it has also been reported that treatment with CoCl2
(160 μmol/l) induced IL-6 and TNFα production in microglia,
resident macrophages in the central nervous system [16]. Cobalt
also induced expression of iNOS (inducible nitric oxide syn-
thase) and NO production. Yang et al. [17] showed that cobalt
increased COX-2 (cyclooxygenase-2) expression and the secre-
tion of IL-6 and IL-8 in human skin keratinocytes in association
with the phosphorylation of NF-κB. Exposure to CoCl2 induced
overproduction of ROS and a reduction in cell viability.
It is difficult at present to reconcile these discrepant results;
however, in vivo experiments generally have shown protective
effects of CoCl2 against inflammatory changes. Although these
results are not supported by other in vitro experiments, this may be
due to a very high concentration of CoCl2 used in these in vitro ex-
periments. Alternatively, some secondary protective effects may
play a role in the in vivo effect of CoCl2.
We have also shown in the present study that treatment with
CoCl2 reduced the activities of MMP-2 and MMP-9 in the aorta;
however, several in vitro studies have shown that cobalt activates
MMPs. Wang et al. [18] have shown that CoCl2 activates MMP-
2 in ligament cells. It has also been shown that the response to
cobalt is different between the anterior cruciate ligament and
medial collateral ligament. Another study showed that CoCl2
increases MMP-2 secretion in articular chondrocytes [19].
It is also difficult to explain the discrepancy in the effects
of cobalt on the activity of MMPs between the present study
and previous studies. One of the possible explanations is that the
effect of cobalt is cell-type specific. Therefore further study is
needed to examine the effect of CoCl2 on MMP production in
macrophages or VSMCs in the future.
Vascular oxidative stress is thought to play an important role
in the pathogenesis of AAA and previous studies have shown that
oxidative stress enhanced AAA development [20,21]. Dubick et
al. [22] reported low levels of Cu,Zn-SOD (copper,zinc SOD)
activity in human aneurysm. Another study reported that CoCl2
inhibited hypoxia-induced oxidative stress in the brain via the
HIF-1α signalling mechanism [23]. The present study showed
that CoCl2 restored the expression of SOD1 and CAT, which was
suppressed in aneurysmal sites. These data suggest that CoCl2 in-
hibited the formation of AAA via antioxidant effects and thereby
suppression of NF-κB phosphorylation and cytokine expression.
Cobalt is a trace element in the body essential for the normal
function of vitamin B12. However, it is well known that excess-
ive intake of cobalt causes cytotoxicity and neurotoxicity and
therefore cobalt cannot be used to treat patients. Recently, sev-
eral PHD inhibitors are under development for clinical use as a
drug for the treatment of anaemia because PHD inhibition causes
up-regulation of EPO through HIF stabilization [24]. PHD inhib-
itors are also expected to be beneficial for ischaemic disorders
[8]. Although it is not clear whether these PHD inhibitors show
the same anti-inflammatory effect as has been shown for CoCl2
in the present study and therefore further study is needed, PHD
inhibitors may be novel promising drugs for the treatment of
AAA.
There are several limitations of the present study. The first
is that, although previous studies [13–15] and the present study
showed that CoCl2 activates the HIF pathway, we could not ex-
clude the possibility of non-specific effects of CoCl2. The second
is that CoCl2 treatment was started before the topical applica-
tion of CaCl2 to the aorta and therefore it is not clear whether
treatment with CoCl2 prevents the progression of dilatation of
established AAA. The third is that Mac-2 can also localize to
fibroblasts and therefore we may have overestimated the number
of adventitial macrophages in Mac-2 staining, which may explain
the larger change in the number of Mac-2-positive cells between
the groups than the changes in aortic dimension (Figures 1B and
1R). Further studies are needed to address these issues.
In conclusion, we have shown in the present study that PHD
inhibition by CoCl2 administration attenuated AAA formation
induced by CaCl2 in association with a reduction in inflammatory
cytokines and the activity of MMP-2 and MMP-9. Although
further study is required to elucidate the detailed mechanisms,
PHD inhibition may be a novel strategy for the prevention of
AAA progression.
CLINICAL PERSPECTIVES
 Inhibition of PHD has been shown to suppress LPS-induced
TNFα expression in a macrophage cell line in a previous
study, but the effect of a PHD inhibitor on AAA development
is unknown.
 In the present study, CoCl2, a PHD inhibitor, prevented the
development of CaCl2-induced AAA in association with re-
duced inflammation and ECM disruption.
 These findings suggest that PHD plays a critical role in the
development of AAA and that there is a therapeutic potential
of PHD inhibitors for the prevention of AAA development.
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